MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Cancer & Oncology Companies _Pharmaceuticals & Biotechnology _ Pancreas, Pancreatic
Erasca Inc. (NASDAQ: ERAS)*
Organization & Developments: Erasca
Parents
Erasca Inc. (NASDAQ: ERAS)*
Children
*Erasca is a developer of oncology drugs intended to provide precision oncology options.
2022: MD Anderson and Erasca announce collaboration on RAS/MAPK-driven cancers
2023: Erasca gains on FDA fast track status for brain cancer therapy_ seekingalpha.com
2023: Erasca: A Pivotal Trial Will Help Make It Stand Out_seekingalpha.com
2024: Erasca: New Focus After Restructuring, But Need More Differentiation
2025: Erasca: Future 'Streamlined' But Still Uncertain
2025: Erasca’s Naporafenib Is Shaping Up Nicely For NRASm Melanoma (NASDAQ:ERAS)
2026: Erasca hits ‘home run’ with cancer data as analyst suggests stock drop prompted by patient death
2026: Erasca touts strong early results in pancreatic and lung cancer therapy trial
2026: With pancreatic cancer drug, Erasca hopes to be biotech's next big thing
8. Erasca
Jumps
*Key People: Erasca
Finance & Acquisitions: Erasca